H.C. Wainwright Sticks to Its Buy Rating for Savara (SVRA)

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Savara (SVRAResearch Report) today and set a price target of $3.00. The company’s shares closed last Friday at $1.71.

According to TipRanks, Fein is an analyst with an average return of -4.4% and a 41.48% success rate. Fein covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals, Vertex Pharmaceuticals, and Concert Pharma.

Savara has an analyst consensus of Moderate Buy, with a price target consensus of $3.00.

See Insiders’ Hot Stocks on TipRanks >>

Based on Savara’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $8.3 million. In comparison, last year the company had a GAAP net loss of $10.22 million

Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SVRA in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Savara, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its products include AeroVanc, Molgradex, GM-CSF, and Aironite. The company was founded on April 27, 2017 and is headquartered in Austin, TX.

Read More on SVRA:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More